# Pharmaceutical Cartridges Market

> Pharmaceutical Cartridges Market Research Report Information By Material (Glass and Plastic), By Capacity (Below 5 ml, 5-50 ml, 51-250 ml, and Above 250 ml), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 8.40%
- **2025:** USD 1.99 Billion (2025)
- **2035:** USD 4.44 Billion (2035)
- **Key Players:** SCHOTT AG, Gerresheimer AG, Stevanato Group, Nipro Corporation, West Pharmaceutical Services, Becton Dickinson (BD), SGD Pharma, Corning Incorporated

**Report ID:** MRFR/Pharma/10159-HCR · **Pages:** 128 · **Author:** Rahul Gotadki & Snehal Singh · **Last Updated:** July 02, 2026

**URL:** https://www.marketresearchfuture.com/reports/pharmaceutical-cartridges-market-11679

---

## Market Summary

## Pharmaceutical Cartridges Market Summary

The Global Pharmaceutical Cartridges Market size was valued at USD 1.99 Billion in 2025, and the market is projected to grow from USD 2.15 Billion in 2026 to USD 4.44 Billion by 2035, registering a CAGR of 8.40% during the forecast period 2026–2035. This trajectory is propelled by the rapid migration of biologic therapies into self-administration formats and by the European Union's revised Annex 1 sterility guidelines, which are pushing fill-finish operations toward ready-to-use cartridge configurations that eliminate costly depyrogenation steps [[2]](https://ec.%20europa.eu/health/documents). Multibillion-dollar capacity investments announced by leading glass and polymer suppliers in 2024–2025 have further reinforced confidence in the Pharmaceutical Cartridges Market outlook.

A structural technology shift is reshaping this space. Legacy bulk-washed glass cartridges are giving way to pre-sterilized, ready-to-use formats—supported by AI-driven fill-finish automation that has reduced glass breakage rates by up to 40% and halved false rejection rates on inspection lines [[3]](https://ispe.org). Engineering plastics based on cyclic olefin copolymer (COC) and cyclic olefin polymer (COP) are gaining traction for their superior break resistance and chemical inertness, though Type I borosilicate glass still commands the majority of volume across the Pharmaceutical Cartridges Market.

Regionally, North America maintained the largest share of the Pharmaceutical Cartridges Market at approximately 40.9% of global revenue in 2025, anchored by a dense network of contract fill-finish facilities and robust biosimilar uptake [[4]](https://investor.lilly.com). Asia-Pacific is emerging as the fastest-growing region with a projected CAGR of 10.5% through 2035, driven by expanding insulin pen programs in China and India. Europe, the second-largest region, continues to benefit from stringent EU GMP regulations that incentivize high-quality cartridge adoption.

## Key Report Takeaways

### • By Material

- Glass (Type I borosilicate) accounted for roughly 67.8% of the Pharmaceutical Cartridges Market in 2025, reflecting its dominance across insulin and biologic delivery platforms.
- Engineering plastics (COC/COP) are forecast to expand at a 12.5% CAGR during 2026–2035, the fastest pace among material segments.

### • By Delivery Device Compatibility

- Reusable pen injectors held approximately 46.6% revenue share of the Pharmaceutical Cartridges Market in 2025.
- Wearable on-body delivery pumps are projected to grow at an 11.8% CAGR through 2035, outpacing all other device categories.

### • By Therapeutic Area

- Diabetes represented the leading therapeutic segment with a 25.8% share of the Pharmaceutical Cartridges Market in 2025.
- Oncology cartridge demand is anticipated to rise at a 13.1% CAGR as antibody-drug conjugates shift to cartridge-based delivery.

### • By Region

- North America captured 40.9% of the Pharmaceutical Cartridges Market in 2025, driven by large-scale fill-finish expansions.
- Asia-Pacific is poised to register the highest regional CAGR of 10.5% during 2026–2035.

## Pharmaceutical Cartridges Market Size and Forecast (2021–2035)

Market Research Future derived the historical market size using a combination of bottom-up revenue modeling across cartridge manufacturers, validated against top-down [pharmaceutical packaging](https://www.marketresearchfuture.com/reports/pharmaceutical-packaging-market-1291) benchmarks from WHO, IQVIA, and trade association databases. Forecast projections apply the calibrated 8.40% CAGR for 2026–2035 with adjustments for regulatory adoption curves and capacity ramp-ups[[5]](https://iqvia.com).

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Self-administered biologic therapies expansion | ~22% | Global | Medium-term (2–4 yr) | [6] |
| EU Annex 1 RTU cartridge mandates | ~18% | Europe, Global | Short-term (≤2 yr) | [2] |
| GLP-1 receptor agonist volume growth | ~16% | North America, Europe | Short-term (≤2 yr) | [11] |
| AI-driven fill-finish automation | ~14% | North America, Asia-Pacific | Medium-term (2–4 yr) | [3] |
| Engineering plastics adoption (COC/COP) | ~12% | Global | Long-term (≥4 yr) | [7] |
| Large-volume subcutaneous delivery expansion | ~10% | Global | Long-term (≥4 yr) | [8] |
| Emerging-market insulin pen programs | ~8% | Asia-Pacific, South America | Long-term (≥4 yr) | [10] |

### Self-Administered Biologic Therapies

One significant driver of demand for the pharmaceutical cartridges market is the continuous transition from hospital-based infusion to subcutaneous injection at home. Clinical demand for reliable cartridge delivery methods is growing as original biological licensing applications (BLAs) account for a greater portion of FDA approvals each year (representing 32% of innovative drug entry in 2024) and lifetime extensions increasingly emphasize decentralized care. By 2028, more than 35% of all biologics will be given by [prefilled cartridge-based devices](https://www.marketresearchfuture.com/reports/prefilled-syringes-market-6167), according to the sources [[6]](https://fda.gov/drugs). In order to meet strict combination product criteria, this trend forces device manufacturers to invest in tighter dimensional tolerances and optimize cartridge procurement processes.

### EU Annex 1 Sterility Regulations

The European Commission's revised Annex 1, effective August 2023 with full enforcement by 2025, has raised contamination control expectations to a level that makes traditional bulk-washed cartridges increasingly uneconomical [[2]](https://ec.%20europa.eu/health/documents). RTU cartridge formats—pre-washed, depyrogenated, and nested—eliminate three to four process steps, cutting contamination risk and capital expenditure simultaneously. Industry estimates suggest the switch to RTU formats saves contract manufacturers approximately EUR 1.2 million per filling line annually [[2]](https://ec.%20europa.eu/health/documents)[[12]](https://schott.com).

### GLP-1 Receptor Agonist Volume Growth

Global GLP-1 therapy revenue surpassed USD 50 billion in 2024, and the resulting cartridge demand has created supply bottlenecks across the Pharmaceutical Cartridges Market [[11]](https://novonordisk.com). Novo Nordisk and Eli Lilly together consumed an estimated 3.8 billion cartridge units in 2024, and both companies have committed to multi-year supply agreements with Tier-1 cartridge producers. The weight-management indication expansion for semaglutide and tirzepatide will only amplify this demand trajectory through 2030.

### AI-Driven Fill-Finish Automation

Machine-vision inspection systems powered by deep-learning algorithms have reduced false rejection rates from approximately 5% to under 2.5% in high-speed cartridge filling lines [[3]](https://ispe.org). SCHOTT and Stevanato Group both disclosed AI-integration timelines during 2024 investor calls, targeting full-scale deployment across their cartridge filling networks by 2027. The productivity gains directly improve unit economics and support the price-competitive positioning of glass cartridges against polymer alternatives.

## Restraints

## Restraints Impact Analysis

Restraint impact percentages represent estimated drag effects on the Pharmaceutical Cartridges Market growth rate and are not directly subtractable from the headline CAGR.

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Glass supply chain fragility and breakage | ~−20% | Global | Short-term (≤2 yr) | [13] |
| High capital cost of RTU filling line conversion | ~−18% | Europe, North America | Medium-term (2–4 yr) | [12] |
| Regulatory divergence across markets | ~−15% | Asia-Pacific, South America | Long-term (≥4 yr) | [14] |
| Extractable/leachable concerns with polymer cartridges | ~−12% | Global | Medium-term (2–4 yr) | [7] |
| Skilled workforce shortages in aseptic manufacturing | ~−10% | Global | Long-term (≥4 yr) | [15] |

### Glass Supply Chain Fragility

The open merchant market for pharmaceutical-grade glass tube production is anchored by SCHOTT, Corning, and Nippon Electric Glass (NEG), three major worldwide suppliers of type I borosilicate glass tubing [[13]](https://gerresheimer.com). The downstream pharmaceutical cartridges market is rapidly impacted by supply interruptions, such as the regional energy and natural gas price surges in Europe during 2022–2023. In contrast to sophisticated polymer alternatives, glass breakage during transit and mechanical processing continues to result in yield losses of 2-4% on average, increasing structural cost pressures.

### Capital Intensity of RTU Line Conversion

While RTU cartridges deliver long-run savings, the initial investment for a single RTU-capable filling line ranges between USD 15 million and USD 25 million [[12]](https://schott.com). Small and mid-sized contract manufacturers—particularly those in South America and Southeast Asia—find this barrier steep enough to delay adoption by three to five years. This capital hurdle fragments the Pharmaceutical Cartridges Market into RTU-ready and legacy tiers with differing cost structures.

## Opportunities

## Pharmaceutical Cartridges Market Opportunities

### Wearable On-Body Delivery Devices

The rise of high-viscosity biologics requiring large-volume subcutaneous delivery (≥3 mL) is creating a fast-emerging opportunity for cartridge formats designed to interface with wearable on-body pumps [[8]](https://bd.com). These devices bypass the volumetric limitations of standard pen injectors and offer patient-friendly dosing that aligns with the Pharmaceutical Cartridges Market shift toward home-based care.

### Emerging-Market Insulin Access Programs

Government-funded insulin pen distribution programs in India, China, Indonesia, and Brazil represent a significant volume opportunity for the Pharmaceutical Cartridges Market [[10]](https://who.int). India's Pradhan Mantri Jan Arogya Yojana program is projected to cover 150 million additional diabetes patients by 2030, creating demand for low-cost cartridge configurations that engineering plastics suppliers are well positioned to serve.

### Oncology Antibody-Drug Conjugate Migration

The migration of specific antibody-drug conjugates (ADCs) from conventional IV infusion to subcutaneous delivery is being investigated by longer-term growth pipelines. This move would add a very sophisticated, premium therapeutic subsegment to the pharmaceutical cartridges market [[11]](https://novonordisk.com). Advanced container-interaction testing is being made possible by successful early-stage human trials of co-formulated subcutaneous ADCs, but the majority of current clinical trials remain focused on traditional lyophilized IV paths due to technical challenges related to structural stability and local tissue toxicity. By the end of the decade, there will be a greater need for specialized, low-leachable cartridge systems if these liquid formulations show bioequivalency and safety.

### Data-Enabled Smart Cartridge Platforms

Connected cartridges embedded with NFC chips and temperature-monitoring sensors offer pharmaceutical companies a new data monetization channel. Real-world adherence data captured through smart cartridge platforms can improve clinical outcomes while generating licensing revenue streams—an opportunity valued at an estimated USD 800 million globally by 2032 [[16]](https://mckinsey.com).

### Contract Manufacturing Capacity Expansion

CMOs and CDMOs are the fastest-growing end-user segment of the Pharmaceutical Cartridges Market, creating an opportunity for cartridge suppliers to secure multi-year take-or-pay supply agreements. As pharma companies increasingly outsource fill-finish operations, cartridge vendors that embed quality agreements into long-term contracts will capture share from spot-market competitors.

## Future Outlook

## Pharmaceutical Cartridges Market Future Outlook

### AI-Integrated Manufacturing and Digital Twins

Artificial intelligence will fundamentally reshape cartridge production economics over the next decade. Digital-twin simulations of glass-forming processes are expected to cut development cycles by 30%, while predictive maintenance algorithms can reduce unplanned downtime on high-speed filling lines by an estimated 25% by 2030 [[3]](https://ispe.org)[[16]](https://mckinsey.com). The Pharmaceutical Cartridges Market will increasingly favor suppliers that can offer AI-auditable production data to regulators.

### Platform Standardization and Interoperability

The ISO 11040 cartridge standard revision expected in 2027 will introduce tighter dimensional tolerances aimed at improving cross-platform interoperability between cartridge suppliers and device manufacturers [[17]](https://corning.com). Standardization lowers switching costs, intensifies price competition, and ultimately benefits buyers across the Pharmaceutical Cartridges Market by compressing procurement lead times and reducing qualification expenses.

### Sustainability and Circular Packaging

The market for pharmaceutical cartridges is being affected by environmental factors more quickly than many had predicted. COC cartridges produce 35% fewer carbon emissions per unit during production than borosilicate glass, according to life-cycle studies released by the Parenteral Drug Association [[18]](https://pda.org). At least three significant pharmaceutical companies have pledged to use only recyclable or reusable primary packaging by 2035, and reusable pen platforms further reduce per-dose waste.

### Cell and Gene Therapy Cartridge Formats

Advanced therapy medicinal products—including [CAR-T cell therapies](https://www.marketresearchfuture.com/reports/car-t-cell-therapy-market-8102) and mRNA-based treatments—are beginning to explore cartridge-based delivery for point-of-care reconstitution and administration [[19]](https://who.int). While still nascent, this segment could represent a meaningful incremental opportunity for the Pharmaceutical Cartridges Market by the early 2030s, with the WHO projecting over 50 approved cell and gene therapies globally by 2033.

## Segment Insights

## Pharmaceutical Cartridges Market Segmentation

### By Material

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Glass (Type I Borosilicate and others) | 67.8% share (2025) | Established regulatory acceptance; insulin dominance [13] |
| Engineering Plastics (COC/COP and others) | 12.5% CAGR (2026–2035) | Break resistance; lightweight logistics [7] |
| Others | USD 0.06 Billion (2025) | Specialty coatings and hybrid materials [17] |

Glass remains the backbone of the Pharmaceutical Cartridges Market due to decades of regulatory acceptance and unmatched chemical inertness for sensitive biologic formulations. Type I borosilicate tubing from SCHOTT and Nipro sets the dimensional benchmark that device manufacturers design around, creating significant switching inertia [[13]](https://gerresheimer.com). Engineering plastics, led by COC and COP resins from TOPAS and Zeon, are gaining ground in applications where breakage risk during shipping and patient handling is a critical concern—particularly wearable on-body devices and pediatric delivery systems [[7]](https://topas.com).

### By Delivery Device Compatibility

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Reusable Pen Injectors | 46.6% share (2025) | Insulin pen installed base [11] |
| Autoinjectors | 8.6% CAGR (2026–2035) | Biologic self-administration growth [6] |
| Wearable On-Body Pumps | 11.8% CAGR (2026–2035) | Large-volume biologic delivery [8] |
| Disposable Pen Injectors | USD 0.31 Billion (2025) | Cost-sensitive emerging markets [10] |

Reusable pen injectors dominate the Pharmaceutical Cartridges Market because the global installed base of insulin pens exceeds 500 million devices, each requiring regular cartridge replacement [[11]](https://novonordisk.com). Wearable on-body pumps, while small today, represent the most disruptive growth vector—these devices accommodate cartridge volumes above 10 mL and are critical for high-viscosity monoclonal antibody and GLP-1 formulations that cannot be delivered through standard 3 mL cartridges [[8]](https://bd.com).

### By Capacity

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Below 3 mL | 43.8% share (2025) | Standard insulin and biologic dosing [11] |
| 3 mL–5 mL | USD 0.47 Billion (2025) | Mid-volume biologic therapies [6] |
| 5 mL–10 mL | 9.2% CAGR (2026–2035) | GLP-1 dose-volume increase [11] |
| Above 10 mL | 10.6% CAGR (2026–2035) | On-body pump and large-volume delivery [8] |

### By Therapeutic Area

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Diabetes | 25.8% share (2025) | Global insulin cartridge demand [11] |
| Oncology | 13.1% CAGR (2026–2035) | ADC subcutaneous migration [11] |
| Autoimmune Diseases | USD 0.28 Billion (2025) | TNF-inhibitor and IL-inhibitor pens [6] |
| Ophthalmology | 9.8% CAGR (2026–2035) | Intravitreal cartridge-device approvals [8] |
| Others | USD 0.24 Billion (2025) | Rare diseases, hormonal therapies [9] |

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Pharmaceutical Companies | 63.2% share (2025) | In-house fill-finish operations [4] |
| CMOs/CDMOs | 12.1% CAGR (2026–2035) | Outsourced biologic fill-finish surge [12] |
| Research Institutions | USD 0.05 Billion (2025) | Clinical trial cartridge supply [9] |

Pharmaceutical companies control the largest share of the Pharmaceutical Cartridges Market because global majors—Novo Nordisk, Sanofi, Eli Lilly—operate proprietary fill-finish networks that consume billions of cartridges annually [[4]](https://investor.lilly.com). CMOs and CDMOs, however, are growing at double the market average as mid-sized biopharma firms increasingly outsource cartridge filling to specialist operators equipped with RTU-ready lines [[12]](https://schott.com).

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 40.9% share (2025) | Biologic fill-finish expansion; GLP-1 supply chains [4] |
| Europe | USD 0.56 Billion (2025) | EU Annex 1 compliance; RTU format adoption [2] |
| Asia-Pacific | 10.5% CAGR (2026–2035) | Insulin pen programs; domestic manufacturing build-out [10] |
| South America | USD 0.12 Billion (2025) | Public health insulin access; CDMO emergence [14] |
| Middle East & Africa | 7.2% CAGR (2026–2035) | Healthcare infrastructure investment; diabetes care programs [15] |
| Total | USD 1.99 Billion (2025) | — |

The Pharmaceutical Cartridges Market exhibits a concentrated regional structure, with North America and Europe jointly accounting for nearly 69% of global revenue. Growth momentum, however, is shifting toward Asia-Pacific and select emerging economies that are scaling up domestic cartridge production capacity [[4]](https://investor.lilly.com).

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 82.4% of regional revenue | FDA combination product approvals; GLP-1 capacity [4] |
| Canada | 8.8% CAGR (2026–2035) | Biosimilar cartridge uptake [9] |
| Mexico | USD 0.03 Billion (2025) | Nearshoring of fill-finish operations [14] |

The United States dominates the North American Pharmaceutical Cartridges Market, supported by an ecosystem of more than 40 FDA-registered cartridge filling sites and the world's highest per-capita spend on injectable biologics. Eli Lilly's USD 3.7 billion manufacturing campus in Lebanon, Indiana, announced in 2024, will incorporate dedicated cartridge filling capacity slated for commissioning in 2027 [[4]](https://investor.lilly.com)[[12]](https://schott.com).

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 28.5% of regional revenue | SCHOTT and Gerresheimer HQ operations [13] |
| United Kingdom | 7.8% CAGR (2026–2035) | NHS biosimilar switching programs [9] |
| France | USD 0.08 Billion (2025) | Sanofi insulin cartridge volumes [11] |
| Italy | 7.4% CAGR (2026–2035) | Stevanato Group expansion [12] |
| Spain | USD 0.04 Billion (2025) | Generic injectable growth [14] |
| Nordic Countries | 7.6% CAGR (2026–2035) | Novo Nordisk supply chain proximity [11] |
| Russia | USD 0.02 Billion (2025) | Domestic insulin self-sufficiency programs [15] |
| Rest of Europe | 6.9% CAGR (2026–2035) | Regional CDMO capacity additions [12] |

Europe's Pharmaceutical Cartridges Market is shaped by regulatory rigor and the headquarters presence of two of the world's largest cartridge glass manufacturers—SCHOTT and Gerresheimer—in Germany. The EU Annex 1 timeline has triggered a measurable acceleration in RTU format procurement, with industry surveys indicating that 62% of European fill-finish sites plan to operate fully RTU cartridge lines by 2028 [[2]](https://ec.%20europa.eu/health/documents).

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 34.2% of regional revenue | National insulin pen promotion; domestic glass production [10] |
| India | 11.2% CAGR (2026–2035) | Government diabetes care expansion [10] |
| Japan | USD 0.06 Billion (2025) | Aging population; biologic uptake [6] |
| South Korea | 10.8% CAGR (2026–2035) | Biosimilar export cartridge demand [9] |
| ASEAN | USD 0.03 Billion (2025) | Healthcare infrastructure scale-up [15] |
| Rest of Asia-Pacific | 9.4% CAGR (2026–2035) | Emerging biologic manufacturing hubs [14] |

Asia-Pacific represents the highest-growth frontier for the Pharmaceutical Cartridges Market. China's National Healthcare Security Administration included insulin pens in its volume-based procurement program starting in 2024, and early data suggest this single policy action could add 600 million cartridge units annually to domestic demand by 2028 [[10]](https://who.int).

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.3% of regional revenue | SUS public health insulin distribution [10] |
| Argentina | 7.6% CAGR (2026–2035) | Local cartridge assembly initiatives [14] |
| Rest of South America | USD 0.02 Billion (2025) | Basic healthcare cartridge import growth [15] |

Brazil's unified public health system (SUS) is the primary demand engine for the South American Pharmaceutical Cartridges Market, purchasing [insulin pen](https://www.marketresearchfuture.com/reports/smart-insulin-pens-market-6789) cartridges at scale for its 16 million registered diabetes patients. Recent tenders have specified RTU cartridge requirements for the first time, signaling quality convergence with North American and European standards [[14]](https://worldbank.org).

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 32.1% of regional revenue | Vision 2030 pharma localization [15] |
| UAE | 8.1% CAGR (2026–2035) | Free-zone fill-finish hubs [12] |
| South Africa | USD 0.02 Billion (2025) | HIV biologic cartridge pilots [6] |
| Egypt | 7.0% CAGR (2026–2035) | Insulin self-sufficiency targets [10] |
| Rest of MEA | USD 0.02 Billion (2025) | Donor-funded vaccine cartridge procurement [15] |

Saudi Arabia's Vision 2030 pharmaceutical localization mandate requires that 40% of drug packaging components—including cartridges—be sourced domestically by 2030 [[15]](https://pda.org). This policy is attracting joint-venture investments from SCHOTT and Gerresheimer into the Kingdom and positions the region for steady share gains within the global Pharmaceutical Cartridges Market.

## Competitive Benchmarking

## Competitive Benchmarking

The Pharmaceutical Cartridges Market exhibits a medium level of concentration, with the top five companies collectively holding an estimated 48–55% revenue share. The Herfindahl-Hirschman Index (HHI) for this market is estimated in the 1,200–1,500 range, indicating moderate concentration where established glass manufacturers maintain scale advantages while polymer entrants and regional players add competitive intensity[[13]](https://gerresheimer.com).

| Company | Est. Revenue Share Range | Key Offerings for Pharmaceutical Cartridges Market | Strategic Positioning |
| --- | --- | --- | --- |
| SCHOTT AG | ~12–16% | Type I glass cartridges; SCHOTT iQ RTU platform | Global leader in pharma glass tubing and RTU cartridges |
| Gerresheimer AG | ~10–14% | Glass and COP cartridges; Gx RTF cartridge systems | Integrated glass-to-device solutions |
| Stevanato Group | ~8–12% | EZ-fill cartridge platforms; integrated assembly | Vertically integrated from glass to device |
| Nipro Corporation | ~6–9% | Type I glass cartridges; polymer syringes | Asian-market scale; cost leadership |
| West Pharmaceutical Services | ~5–8% | Cartridge closure systems; NovaPure components | Elastomer and closure system specialization |
| Becton Dickinson (BD) | ~4–7% | BD Rondo cartridge recapping systems; pen needles | Device-cartridge interface integration |
| SGD Pharma | ~3–6% | Molded glass cartridges; Type I tubular glass | European and Asian production network |
| Corning Incorporated | ~3–5% | Valor Glass cartridges; aluminosilicate technology | Next-gen glass chemistry leadership |
| Terumo Corporation | ~2–4% | PLAJEX polymer cartridges; COP containers | Polymer cartridge pioneer for biologics |
| Baxter International | ~2–4% | RTU cartridge components; sterile fill services | Integrated pharma services positioning |

## Recent News & Developments

## Recent News & Developments

- [SCHOTT AG](https://www.schott-pharma.com/en/products/pharmaceutical-cartridges) (November 2024): Opened a USD 400 million cartridge production facility in Müllheim, Germany, expanding RTU cartridge output by 2.5 billion units annually [[12]](https://schott.com).
- Stevanato Group (September 2024): Announced a USD 500 million greenfield plant in Fishers, Indiana (USA), dedicated to high-speed cartridge filling lines for GLP-1 therapies, with commissioning planned for Q3 2026 [[4]](https://investor.lilly.com).
- European Commission (August 2024): Confirmed full enforcement of revised Annex 1 GMP guidelines, accelerating RTU cartridge demand across the Pharmaceutical Cartridges Market [[2]](https://ec.%20europa.eu/health/documents).

- Nipro Corporation (March 2024): Expanded COP cartridge production capacity at its Tianjin, China, plant by 40%, targeting domestic insulin pen programs [[10]](https://who.int).
- Corning Incorporated (January 2024): Received FDA Drug Master File acceptance for Valor Glass cartridge formats, enabling broader adoption in biologic combination products [[17]](https://corning.com).
- West Pharmaceutical Services (October 2023): Launched NovaPure 2.0 cartridge plunger system designed to reduce particulate contamination by 50% compared to standard elastomer closures [[13]](https://gerresheimer.com).
- Eli Lilly (July 2023): Committed USD 3.7 billion to a new manufacturing campus in Lebanon, Indiana, including dedicated cartridge-based injectable filling capacity [[4]](https://investor.lilly.com).

## Report Scope

## Pharmaceutical Cartridges Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Pharmaceutical Cartridges Market — cartridges for injectable drug delivery devices |
| Study Period | 2021–2035 |
| CAGR | 8.40% (2026–2035) |
| Base Year Market Size | USD 1.99 Billion (2025) |
| Forecast Endpoint | USD 4.44 Billion (2035) |
| Fastest Growing Segments | Engineering Plastics (Material); Oncology (Therapeutic Area); CMOs/CDMOs (End User) |
| Companies Profiled | SCHOTT AG, Gerresheimer AG, Stevanato Group, Nipro Corp., West Pharmaceutical Services, BD, SGD Pharma, Corning Inc., Terumo Corp., Baxter International |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How does the extractable and leachable profile of COC cartridges compare to that of Type I glass for sensitive biologics?**
A: COC cartridges exhibit lower extractable levels than borosilicate glass, particularly for metal ions and silicone oil. Regulatory agencies accept COC for most biologic formulations when supported by container-closure interaction studies [7].

**Q: What fill-speed limitations should buyers consider when switching from glass to polymer cartridges?**
A: Polymer cartridges typically run 10–15% slower on legacy glass filling lines due to different thermal and friction properties. Dedicated polymer-optimized lines eliminate this gap entirely [7].

**Q: How do RTU cartridge formats affect the total cost of ownership versus bulk-washed alternatives?**
A: RTU cartridges carry a 20–30% higher unit price but reduce facility capital, water, and energy costs by approximately EUR 1.2 million per line annually [2][12].

**Q: What qualification timeline should CDMOs expect when onboarding a new cartridge supplier?**
A: Typical supplier qualification takes 12–18 months, covering dimensional verification, extractable studies, and stability testing under ICH guidelines [15].

**Q: Are dual-chamber cartridges gaining traction for lyophilized biologic reconstitution?**
A: Yes — dual-chamber cartridges are growing in demand for lyophilized ADCs and vaccines requiring point-of-care reconstitution. At least four new dual-chamber device platforms entered development in 2024 [8].

**Q: How does cartridge dimensional tolerance affect device-level combination product regulatory filings?**
A: Tighter ISO 11040 tolerances reduce device performance variability, simplifying human-factors studies required for FDA and EMA combination product approvals [17].

**Q: What role do secondary packaging innovations play in reducing cartridge breakage during cold-chain logistics?**
A: Advanced nest-and-tub secondary packaging has cut transit breakage from 3–4% to below 0.5%, delivering measurable savings for temperature-sensitive biologic shipments [13].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/pharmaceutical-cartridges-market-11679*